Irx Therapeutics
Ernexa Therapeutics, based in Cambridge, Massachusetts, specializes in developing innovative cell therapies aimed at treating advanced cancer and autoimmune diseases. Their core technology revolves around engineering induced pluripotent stem cells (iPSCs) into mesenchymal stem cells (iMSCs), enabling scalable, off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
The company's lead therapy, ERNA-101, targets ovarian cancer by enhancing the immune system's ability to recognize and attack cancer cells, while ERNA-201 addresses inflammation in autoimmune diseases by calming overactive immune responses. Both therapies leverage the natural tumor-homing abilities of iMSCs to deliver potent cytokines directly to affected sites, representing a significant advancement in targeted treatment options.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.